Larimar Therapeutics (LRMR) Stock Forecast & Price Target

$7.15

+0.30 (+4.38%)

(As of 02:38 PM ET)

Larimar Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for Larimar Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 6 have given a buy rating, and 1 has given a strong buy rating for LRMR.

Consensus Price Target

$20.00
179.72% Upside

High Forecast	$25.00
Average Forecast	$20.00
Low Forecast	$14.00

According to the 7 analysts' twelve-month price targets for Larimar Therapeutics, the average price target is $20.00. The highest price target for LRMR is $25.00, while the lowest price target for LRMR is $14.00. The average price target represents a forecasted upside of 179.72% from the current price of $7.15.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.00	$21.33	$21.33	$11.83
Forecasted Upside	179.72% Upside	173.97% Upside	173.97% Upside	180.19% Upside

Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad)

Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.

This means you must act NOW before it's too late.

LRMR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LRMR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Larimar Therapeutics Stock vs. The Competition

Type	Larimar Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.14	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	191.97% Upside	1,006.91% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/4/2024	Baird R W 0 of 5 stars	B. Skorney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2024	Robert W. Baird 2 of 5 stars		Initiated Coverage	Outperform	$16.00	+131.21%
5/31/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$25.00 ➝ $25.00	+214.07%
5/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$10.00 ➝ $14.00	+74.13%
4/3/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Park Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/3/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$25.00	+239.67%
2/20/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Jubinville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/15/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/17/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$12.00 ➝ $14.00	+283.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:12 PM ET.

LRMR Forecast - Frequently Asked Questions

What is Larimar Therapeutics' forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Larimar Therapeutics is $20.00, with a high forecast of $25.00 and a low forecast of $14.00.
Should I buy or sell Larimar Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LRMR shares.
Does Larimar Therapeutics's stock price have much upside?: According to analysts, Larimar Therapeutics's stock has a predicted upside of 164.20% based on their 12-month stock forecasts.
Has Larimar Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Larimar Therapeutics's stock had 1 upgrade by analysts.
What analysts cover Larimar Therapeutics?: Larimar Therapeutics has been rated by research analysts at Baird R W, and Robert W. Baird in the past 90 days.
Do Wall Street analysts like Larimar Therapeutics more than its competitors?: Analysts like Larimar Therapeutics more than other "medical" companies. The consensus rating for Larimar Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LRMR compares to other companies.